Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
暂无分享,去创建一个
[1] A. Antonini,et al. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey. , 1995, Nuclear medicine and biology.
[2] T. Ishikawa,et al. The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] K. Herholz,et al. Discordant twins with Parkinson's disease: Positron emission tomography and early signs of impaired cognitive circuits , 1994, Annals of neurology.
[4] S. Gilman,et al. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy , 1994, Annals of neurology.
[5] A. Antonini,et al. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease , 1994, Neurology.
[6] T. Chase,et al. Wearing‐off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms , 1994, Annals of neurology.
[7] H. Kimura,et al. Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels , 1993, Annals of neurology.
[8] R S Frackowiak,et al. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. , 1993, Brain : a journal of neurology.
[9] K. Leenders,et al. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. , 1993, Archives of neurology.
[10] D. Margouleff,et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease , 1993, Annals of neurology.
[11] H. Beer,et al. An improved synthesis of No-carrier-added (NCA) 6-[18F]fluoro-L-DOPA and its remote routine production for PET investigations of dopaminergic systems , 1993 .
[12] P. Boesiger,et al. T2 relaxation time in patients with Parkinson's disease , 1993, Neurology.
[13] Yaakov Stern,et al. Relationships between extrapyramidal signs and cognitive function in a community‐dwelling cohort of patients with Parkinson's disease and normal elderly individuals , 1993, Annals of neurology.
[14] H G Wieser,et al. Mesiobasal versus lateral temporal lobe epilepsy , 1993, Neurology.
[15] Richard S. J. Frackowiak,et al. The identification of presymptomatic parkinsonism: Clinical and {18F}dopa positron emission tomography studies in an irish kindred , 1992, Annals of neurology.
[16] T. Gasser,et al. 123I‐iodobenzamide‐SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism , 1992, Neurology.
[17] J. Nutt,et al. Differences in the Motor Response to Apomorphine Between Untreated and Fluctuating Patients With Parkinson's Disease , 1992, Clinical neuropharmacology.
[18] Richard S. J. Frackowiak,et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.
[19] S. Carmichael,et al. Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients , 1991, Annals of neurology.
[20] L. Deecke,et al. Dopamine D2 Receptor Imaging with SPECT: Studies in Different Neuropsychiatric Disorders , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[21] T Jones,et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. , 1990, Archives of neurology.
[22] G. E. Alexander,et al. Functional architecture of basal ganglia circuits: neural substrates of parallel processing , 1990, Trends in Neurosciences.
[23] J. Rinne,et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.
[24] J R Moeller,et al. The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies , 1990, Movement disorders : official journal of the Movement Disorder Society.
[25] A J Lees,et al. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. , 1989, Journal of neurology, neurosurgery, and psychiatry.
[26] P. Seeman,et al. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain , 1989, Synapse.
[27] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.
[28] K. L. Leenders,et al. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers , 1988, Brain Research.
[29] J. Korf,et al. Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography (PET) , 1987, Journal of the Neurological Sciences.
[30] T. Högberg,et al. Synthesis of [methoxy-3H]- and [methoxy-11C]- labelled raclopride. Specific dopamine-D2 receptor ligands , 1987 .
[31] S J Kish,et al. Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.
[32] T Jones,et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.
[33] K. Hamacher,et al. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] C. Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[35] A. Lang,et al. Striatal dopamine distribution in Parkinsonian patients during life , 1985, Journal of the Neurological Sciences.
[36] D. Brooks,et al. PRE-SYNAPTIC AND POST-SYNAPTIC DOPAMINERGIC SYSTEM IN HUMAN BRAIN , 1984, The Lancet.
[37] R Harrop,et al. Cerebral Glucose Metabolism in Parkinson’s Disease , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.